BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 33233970)

  • 1. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
    Onesti CE; Jerusalem G
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):283-298. PubMed ID: 33233970
    [No Abstract]   [Full Text] [Related]  

  • 2. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4-6 inhibitors in breast cancer: current status and future development.
    Choo JR; Lee SC
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology.
    Thibault S; Hu W; Hirakawa B; Kalabat D; Franks T; Sung T; Khoh-Reiter S; Lu S; Finkelstein M; Jessen B; Sacaan A
    Mol Cancer Ther; 2019 Feb; 18(2):257-266. PubMed ID: 30401694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can CDK4/6 inhibitors cause fatal lung injury?
    Jazieh KA; Budd GT; Dalpiaz N; Abraham J
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):917-919. PubMed ID: 31566017
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6 blockade in breast cancer: current experience and future perspectives.
    Zardavas D; Pondé N; Tryfonidis K
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
    Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK
    Breast Cancer Res Treat; 2019 Feb; 174(1):271-278. PubMed ID: 30465154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
    J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer.
    Ratosa I; Orazem M; Scoccimarro E; Steinacher M; Dominici L; Aquilano M; Cerbai C; Desideri I; Ribnikar D; Marinko T; Livi L; Meattini I
    Clin Breast Cancer; 2020 Dec; 20(6):495-502. PubMed ID: 32622736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.
    Braal CL; Jongbloed EM; Wilting SM; Mathijssen RHJ; Koolen SLW; Jager A
    Drugs; 2021 Feb; 81(3):317-331. PubMed ID: 33369721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
    El Hachem G; Gombos A; Awada A
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):81-92. PubMed ID: 33054442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
    Poratti M; Marzaro G
    Eur J Med Chem; 2019 Jun; 172():143-153. PubMed ID: 30978559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning.
    Kulkarni A; Singh J
    Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):225-233. PubMed ID: 38600865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.